Key Developments: Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

2.76USD
19 Dec 2014
Price Change (% chg)

$0.24 (+9.52%)
Prev Close
$2.52
Open
$2.44
Day's High
$2.79
Day's Low
$2.44
Volume
279,554
Avg. Vol
143,700
52-wk High
$5.23
52-wk Low
$2.25

Search Stocks

Latest Key Developments (Source: Significant Developments)

Targacept Inc appoints interim CFO - Form 8-K
Tuesday, 16 Dec 2014 04:03pm EST 

Targacept Inc:Appoints Mauri K. Hodges to serve on an interim basis as the company‚Äôs vice president, finance and administration, chief financial officer and treasurer, effective immediately.  Full Article

Targacept Inc announces resignation of CFO - Form 8-K
Friday, 14 Nov 2014 08:31am EST 

Targacept Inc:Says on Nov. 10, Alan A. Musso resigned from his position as Senior Vice President, Finance and Administration, Chief Financial Officer and Treasurer of the company.  Full Article

Targacept Inc reaffirms FY 2014 revenue outlook
Wednesday, 6 Aug 2014 07:35am EDT 

Targacept Inc:Says it continues to not expect significant operating revenues for FY 2014.  Full Article

Targacept Inc's phase 2b clinical trial in Alzheimer's disease does not show superiority of TC-1734 over donepezil
Monday, 14 Jul 2014 03:06pm EDT 

Targacept Inc:Announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease.In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment.Trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil.Co-primary endpoints for the study were measures of cognitive function and global function.Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.  Full Article

Targacept Inc gives FY 2014 revenue outlook
Thursday, 13 Feb 2014 07:30am EST 

Targacept Inc:Says for FY 2014 it does not expect significant operating revenues.FY 2014 revenue of $0.50 mln - Thomson Reuters I/B/E/S.  Full Article

Targacept Inc appoints John P. Richard as Chairman
Wednesday, 8 Jan 2014 08:55am EST 

Targacept Inc:Says John P. Richard has been appointed as the company's Chairman of the Board effective Jan. 1.  Full Article

Targacept Inc announces negative top-line results from Phase 2b clinical trial of TC-5619 in Schizophrenia
Monday, 16 Dec 2013 04:05pm EST 

Targacept Inc:Says top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.Says in the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the Scale for the Assessment of Negative Symptoms (SANS) after 24 weeks versus placebo.Says iIn addition, TC-5619 did not demonstrate improvement on the key secondary measures of cognitive function.Says TC-5619 exhibited a benign safety and tolerability profile in the study.  Full Article

Targacept Inc Announces Amendment To Its Collaboration With AstraZeneca
Tuesday, 5 Mar 2013 07:00am EST 

Targacept Inc announced that its collaboration with AstraZeneca has been restructured. Under the new terms:Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator in any therapeutic area, including cognitive disorders and schizophrenia, without obligation to AstraZeneca. Previously, AstraZeneca held an option to license any such compound that was developed by Targacept for a cognitive disorder or schizophrenia. Targacept has several alpha7 NNR modulators in its portfolio; AstraZeneca now has the right to develop and commercialize the alpha4beta2 NNR modulators that it has licensed from Targacept under the collaboration, including AZD1446, in any therapeutic area. Previously, AstraZeneca`s rights with regard to these compounds were limited to cognitive disorders and schizophrenia; AstraZeneca will return to Targacept all rights to the alpha4beta2 modulator TC-1734 (also known as AZD3480), which is currently in a Phase 2b clinical trial in mild to moderate Alzheimer`s disease.  Full Article

Targacept Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates
Wednesday, 13 Feb 2013 04:05pm EST 

Targacept Inc announced that for fiscal 2013, it expects operating revenues to be approximately $2.4 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $3.0 million for fiscal 2013.  Full Article

Targacept discontinues bladder drug, shares plunge

- Targacept Inc said it was stopping development of a drug to treat overactive bladder after it failed to show significant reduction in incontinence in a mid-stage study.

Search Stocks